These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20564841)

  • 21. [Medication of the month. Dabigatran etixilate (Pradaxa): an oral anticoagulant acting as a direct selective inhibitor of thrombin].
    Lancellotti P; Scheen AJ
    Rev Med Liege; 2010 Oct; 65(10):588-92. PubMed ID: 21128366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing postsurgical venous thromboembolism: pharmacological approaches.
    Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
    Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [From old to new anticoagulants: the role of the biologist].
    Samama M; Depasse F
    Ann Biol Clin (Paris); 2009; 67(5):525-34. PubMed ID: 19789124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical management of the new anticoagulants].
    Zapata Wainberg G; Ximénez-Carrillo Rico A; Vivancos Mora J
    Neurologia; 2012 Mar; 27 Suppl 1():33-8. PubMed ID: 22682208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should dabigatran replace warfarin for stroke prevention in AF?
    Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
    Sattari M; Lowenthal DT
    Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anticoagulants for treatment of venous thromboembolism.
    Gross PL; Weitz JI
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):380-6. PubMed ID: 18296593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New oral anticoagulants in the ED setting: a review.
    Pollack CV
    Am J Emerg Med; 2012 Nov; 30(9):2046-54. PubMed ID: 22795419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic approach to the bleeding in association with "old" and "new" anticoagulants].
    Dulíček P
    Vnitr Lek; 2012; 58(7-8):559-63. PubMed ID: 23067175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.